Related Experiment Video

Updated: Oct 28, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Anguinomycins C and D, new antitumor antibiotics with selective cytotoxicity against transformed cells

Y Hayakawa1, K Y Sohda, K Shin-Ya

  • 1Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan.

The Journal of Antibiotics
|September 1, 1995
PubMed

Insights

Researchers discovered new antibiotics, anguinomycins C and D, from an actinomycete strain. These compounds target cancer cells with inactivated retinoblastoma protein (pRB), inducing cell death in transformed cells and growth arrest in normal cells.

Area of Science:

  • * Molecular biology
  • * Microbiology
  • * Pharmacology

Background:

  • * The retinoblastoma protein (pRB) plays a crucial role in cell cycle regulation and is frequently inactivated in various human cancers.
  • * Identifying novel therapeutic agents targeting cancer cells with pRB dysfunction is a significant challenge in oncology.

Purpose of the Study:

  • * To screen for novel antitumor antibiotics effective against cancer cells with inactivated retinoblastoma protein (pRB).
  • * To isolate, elucidate the structure of, and characterize the biological activity of newly discovered compounds.

Main Methods:

  • * Screening of actinomycete strains using pRB-inactivated cancer cells.
  • * Isolation and purification of active substances.
  • * Structure elucidation using Nuclear Magnetic Resonance (NMR) spectral analysis.
  • * Assessment of biological activity, including induction of growth arrest and cell death.

Main Results:

  • * Discovery and isolation of two new actinomycete-derived compounds, anguinomycins C and D, belonging to the leptomycin-anguinomycin family.
  • * Anguinomycins C and D demonstrated differential effects: inducing growth arrest in normal cells and cell death in transformed cells with inactivated pRB.
  • * The efficacy against transformed cells was observed when pRB was inactivated by viral oncoproteins like HPV E7, Ad E1A, and SV40 large T antigen.

Conclusions:

  • * Anguinomycins C and D represent a novel class of antibiotics with potential antitumor activity, particularly against cancers characterized by pRB inactivation.
  • * These compounds exhibit selective toxicity, targeting cancer cells while affecting normal cells differently, suggesting a promising therapeutic avenue.
  • * Further investigation into the mechanism of action and therapeutic potential of anguinomycins is warranted.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...